The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASH 2015 | Combination treatment regimens for CLL

Name: Combination treatment regimens for CLL
Uploaded: 2015-12-04T00:00:00.000Z
Duration: 2 min 43 s
Description: At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc, and Stephan Stilgenbauer, MD, discuss drug combination approaches in chronic lymphocytic leukemia (CLL) therapy. Targeting multiple molecules or pathways may have the potential to improve treatment response.

John Gribben and Stephan Stilgenbauer • 4 Dec 2015

ASH 2015

Chronic Lymphocytic Leukemia

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc, and Stephan Stilgenbauer, MD, discuss drug combination approaches in chronic lymphocytic leukemia (CLL) therapy. Targeting multiple molecules or pathways may have the potential to improve treatment response.